Table 3 Summary of efficacy endpoints... | American Society of Hematology

Table 3

Summary of efficacy endpoints

Endpoints	No. (%)	[95% CI] or (range)
Overall CR + CRi + PR	16 (41)	[26%, 58%]
CR+CRi	12 (31)	[17%, 48%]
Median duration of CR+CRi, wk	20.5	(3.8-273.3)
CR	10 (26)	[13%, 42%]
Median duration of CR, wk	27	(4.1-273.3)
CRi	2 (5)	—
PR in T-ALL patients*	4 (10)
CR + CRi + PR	11 (42)	[23%, 63%]
CR+CRi	8 (31)	[14%, 52%]
PR in T-LBL patients†
CR + CRi + PR	5 (38)	[14%, 68%]
CR	4 (31)	[9%, 61%]
DFS, median wks	20	(11-56)
DFS at 1 year	7 (25)	[6%, 50%]
OS, median wks	20	(13-36)
Survival at 1 year	7 (28)	[15%, 43%]

Endpoints	No. (%)	[95% CI] or (range)
Overall CR + CRi + PR	16 (41)	[26%, 58%]
CR+CRi	12 (31)	[17%, 48%]
Median duration of CR+CRi, wk	20.5	(3.8-273.3)
CR	10 (26)	[13%, 42%]
Median duration of CR, wk	27	(4.1-273.3)
CRi	2 (5)	—
PR in T-ALL patients*	4 (10)
CR + CRi + PR	11 (42)	[23%, 63%]
CR+CRi	8 (31)	[14%, 52%]
PR in T-LBL patients†
CR + CRi + PR	5 (38)	[14%, 68%]
CR	4 (31)	[9%, 61%]
DFS, median wks	20	(11-56)
DFS at 1 year	7 (25)	[6%, 50%]
OS, median wks	20	(13-36)
Survival at 1 year	7 (28)	[15%, 43%]

CR indicates complete remission; CR_i, incomplete remission; CR+CRi, complete remission with or without hematologic recovery, PR, partial remission; DFS, disease-free survival; OS, overall survival.

N = 26.

N = 13.